{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Albireo Pharma, Inc."},"Symbol":{"label":"Symbol","value":"ALBO"},"Address":{"label":"Address","value":"53 STATE STREET 19TH FLOOR, BOSTON, Massachusetts, 2109, United States"},"Phone":{"label":"Phone","value":"+1 857 254-5555"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases."},"CompanyUrl":{"label":"Company Url","value":"https://www.albireopharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Jan Peter Mattsson","title":"Chief Scientific Officer, Managing Director-Sweden"},{"name":"Joan Connolly","title":"Chief Technology Officer"},{"name":"Ronald H. W. Cooper","title":"President, Chief Executive Officer &amp; Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}